SEC filings
Cencora (COR)
Recent filings Cencora made with the SEC, newest first. Most have a short AI-generated summary, and every one links to the original.
CIK 0001140859All filings on SEC.gov
8-KCurrent report
Regulation FD Disclosure
Cencora completed a restructuring of its operating model and will begin reporting under a new structure in the first quarter of fiscal 2027, with segments Pharmaceutical Distribution and Services, Specialty Pharmaceutical and Provider…
8-KCurrent report
Results of Operations and Financial Condition; Regulation FD Disclosure
Cencora reported fiscal 2026 fourth-quarter revenue of $88.4 billion, up 5.5 percent, with adjusted diluted EPS of $4.66, and full-year revenue of $337.4 billion, up 5.0 percent. …
8-KCurrent report
Results of Operations and Financial Condition; Regulation FD Disclosure
Cencora signed a definitive agreement to acquire American Oncology Network, a physician-led network of more than 350 oncology providers across 21 states, in a transaction valuing AON at $2.4 billion enterprise value, consisting of $2.3…
8-KCurrent report
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Regulation FD Disclosure
Cencora elected Robert E. Sanchez, Executive Chair of Ryder System, as a new independent director effective October 1, 2026, expanding its board from ten to eleven members. Cencora Chair Mark Durcan and CEO Robert P. …
8-KCurrent report
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
On August 13, 2026, Lorence H. Kim, M.D. resigned from Cencora's board effective immediately in connection with his appointment as Chief Financial Officer of Commonwealth Fusion Systems, Inc. …
8-KCurrent report
Regulation FD Disclosure
Cencora said that certain Walgreens volume serviced separately from the prime vendor agreement began moving outside the company on July 1, 2026, while the prime vendor agreement itself remains unchanged and represents the vast majority of…
10-QQuarterly report
Quarterly report
Cencora's revenue rose 5.1% to $84.75 billion for the quarter ended June 30, 2026, and 4.8% to $249.0 billion for the nine-month period, driven by growth in both of its reportable segments and by a 25.5% increase in sales of GLP-1 diabetes…
8-KCurrent report
Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Cencora, Inc. and subsidiary Innomar Strategies Inc. entered into an amended and restated multi-currency senior unsecured revolving credit facility on July 31, 2026, raising aggregate commitments from $5.5 billion to $7.0 billion and…
8-KCurrent report
Results of Operations and Financial Condition; Regulation FD Disclosure
Cencora reported fiscal 2026 third-quarter revenue of $84.8 billion, up 5.1 percent year over year, with GAAP diluted EPS of $3.94 and adjusted diluted EPS of $4.48, and raised its full-year adjusted diluted EPS guidance to $17.75–$17.95…
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.
Follow Cencora in Readster
Add Cencora to your watchlist and its SEC filings reach your brief alongside the news about it, every line cited to its source. Readster also follows topics, people, newsletters and podcasts.
No credit card. When the trial ends, you move to Readster Free unless you subscribe.